Advanced Therapy Medicinal Products (ATMPs) are revolutionary medicines based on cells, tissues, or genes, offering new possibilities for treating a wide range of diseases and conditions. In a strategic move to map the ever-evolving landscape of cell and gene therapies, the Lund Stem Cell Center initiated a comprehensive exercise in 2022.
The primary objective was to provide a comprehensive overview of therapies in development, assess research progress, and chart a course to expedite the growth of ATMPs in Sweden. The report identifies and characterizes early-stage projects and investigates their progress.
Elias Uhlin, Project Manager of the Lund Stem Cell Center Pre-GMP Facility, who was responsible for compiling the report surveyed 44 Principal Investigators and collaborators at the Center over the course of the past year. With 23 ongoing ATMP projects identified, the mapping exercise revealed more therapies than anticipated, highlighting similarities in needed support among academic researchers, and shared methodologies employed in early-stage ATMP development. In addition to offering insights into ongoing projects, the report aims to inspire other institutions to embark on similar investigations, contributing to a more complete understanding of the ATMP landscape in Sweden.
“The ATMP Pipeline Report is a big step towards shaping the future of advanced therapies and underlines the importance of continued investment in research, development, and collaboration to unlock the full potential of these treatments. By collecting this type of information, we can now better plan for the future when it comes to infrastructure investments and connecting with stakeholders further downstream in the ATMP pipeline,” says Elias Uhlin.
